Home » Reports » Hikma Pharmaceuticals Plc 16.2% Potential Upside Indicated by JP Morgan Cazenove

Hikma Pharmaceuticals Plc 16.2% Potential Upside Indicated by JP Morgan Cazenove

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Upgrades’ with the recommendation being set at ‘OVERWEIGHT’ this morning by analysts at JP Morgan Cazenove. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set a target price of 2400 GBX on its stock. This now indicates the analyst believes there is a possible upside of 16.2% from the opening price of 2065 GBX. Over the last 30 and 90 trading days the company share price has increased 185.5 points and increased 101.5 points respectively. The 1 year high stock price is 2228.61 GBX while the 52 week low for the stock is 1553 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,905.94 GBX and a 200 Day Moving Average share price is recorded at 1,950.18. There are currently 242,329,031 shares in issue with the average daily volume traded being 776,605. Market capitalisation for LON:HIK is £5,249,021,932 GBP.

Join us on our new LinkedIn page

Follow us on LinkedIn